• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为生物活性描述符的分子场极值:定义与验证

Molecular field extrema as descriptors of biological activity: definition and validation.

作者信息

Cheeseright Tim, Mackey Mark, Rose Sally, Vinter Andy

机构信息

Cresset Biomolecular Discovery Ltd., Spirella Building, Letchworth, Hertfordshire SG6 1ET, United Kingdom.

出版信息

J Chem Inf Model. 2006 Mar-Apr;46(2):665-76. doi: 10.1021/ci050357s.

DOI:10.1021/ci050357s
PMID:16562997
Abstract

The paper describes the generation of four types of three-dimensional molecular field descriptors or 'field points' as extrema of electrostatic, steric, and hydrophobic fields. These field points are used to define the properties necessary for a molecule to bind in a characteristic way into a specified active site. The hypothesis is that compounds showing a similar field point pattern are likely to bind at the same target site regardless of structure. The methodology to test this idea is illustrated using HIV NNRTI and thrombin ligands and validated across seven other targets. From the in silico comparisons of field point overlays, the experimentally observed binding poses of these ligands in their respective sites can be reproduced from pairwise comparisons.

摘要

该论文描述了四种三维分子场描述符或“场点”的生成,这些描述符是静电场、立体场和疏水场的极值。这些场点用于定义分子以特定方式结合到指定活性位点所需的性质。其假设是,无论结构如何,显示相似场点模式的化合物可能在同一靶点结合。使用HIV非核苷逆转录酶抑制剂(NNRTI)和凝血酶配体说明了测试这一想法的方法,并在其他七个靶点上进行了验证。通过场点叠加的计算机模拟比较,可以从成对比较中重现这些配体在各自位点的实验观察到的结合姿势。

相似文献

1
Molecular field extrema as descriptors of biological activity: definition and validation.作为生物活性描述符的分子场极值:定义与验证
J Chem Inf Model. 2006 Mar-Apr;46(2):665-76. doi: 10.1021/ci050357s.
2
Predicting anti-HIV activity of dimethylaminopyridin-2-ones: computational approach using topochemical descriptors.预测二甲基氨基吡啶 -2- 酮的抗 HIV 活性:使用拓扑化学描述符的计算方法。
Chem Biol Drug Des. 2009 Feb;73(2):258-70. doi: 10.1111/j.1747-0285.2008.00766.x.
3
Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields.AMANDA的开发与验证,一种用于在分子相互作用场中选择高度相关区域的新算法。
J Chem Inf Model. 2008 Sep;48(9):1813-23. doi: 10.1021/ci800037t. Epub 2008 Aug 12.
4
3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.基于两个战略考量得到的关于临床相关K103N突变型HIV-1逆转录酶的3D-QSAR模型。
Bioorg Med Chem Lett. 2008 Feb 1;18(3):1181-94. doi: 10.1016/j.bmcl.2007.11.134. Epub 2007 Dec 8.
5
A self-organizing algorithm for molecular alignment and pharmacophore development.一种用于分子比对和药效团开发的自组织算法。
J Comput Chem. 2008 Apr 30;29(6):965-82. doi: 10.1002/jcc.20854.
6
Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives.抗HIV-1-苯氨基-1H-咪唑衍生物细胞毒性数据的比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)模型的开发。
Eur J Med Chem. 2009 Jun;44(6):2400-7. doi: 10.1016/j.ejmech.2008.09.043. Epub 2008 Oct 10.
7
Elucidating molecular overlays from pairwise alignments using a genetic algorithm.使用遗传算法从成对序列比对中阐明分子重叠。
J Chem Inf Model. 2009 Jul;49(7):1847-55. doi: 10.1021/ci900109n.
8
3D-QSAR design of novel antiepileptic sulfamides.新型抗癫痫磺酰胺类化合物的3D-QSAR设计
Bioorg Med Chem. 2007 Feb 1;15(3):1556-67. doi: 10.1016/j.bmc.2006.06.010. Epub 2006 Dec 8.
9
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.PIM-1激酶的黄酮类抑制剂的比较分子场分析
Bioorg Med Chem. 2007 Oct 1;15(19):6463-73. doi: 10.1016/j.bmc.2007.06.025. Epub 2007 Jun 14.
10
Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.基于结构的先导化合物发现与优化中的构象排序:评分函数开发的当前趋势
Curr Opin Drug Discov Devel. 2007 May;10(3):308-15.

引用本文的文献

1
Design of inhibitors to Klebsiella pneumoniae aspartate semialdehyde dehydrogenase towards hospital-acquired infections.针对医院获得性感染的肺炎克雷伯菌天冬氨酸半醛脱氢酶抑制剂的设计
Mol Divers. 2025 Jul 5. doi: 10.1007/s11030-025-11277-5.
2
Identification of prochlorperazine dimaleate as a Sortase A inhibitor from FDA libraries for MRSA infection treatment.从美国食品药品监督管理局(FDA)的文库中鉴定出马来酸氯丙嗪作为一种用于治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的分选酶A抑制剂。
RSC Adv. 2025 Jun 25;15(27):21666-21677. doi: 10.1039/d5ra01781e. eCollection 2025 Jun 23.
3
Understanding the substrate recognition and catalytic mechanism of 2-O-methyl fucosidases from glycoside hydrolase family 139.
了解糖苷水解酶家族139中2-O-甲基岩藻糖苷酶的底物识别和催化机制。
J Biol Chem. 2025 Jun 20;301(8):110407. doi: 10.1016/j.jbc.2025.110407.
4
Active Learning FEP Using 3D-QSAR for Prioritizing Bioisosteres in Medicinal Chemistry.使用3D-QSAR的主动学习自由能微扰法在药物化学中对生物电子等排体进行优先级排序
ACS Med Chem Lett. 2025 Apr 29;16(6):984-990. doi: 10.1021/acsmedchemlett.4c00554. eCollection 2025 Jun 12.
5
Understanding the HIV-CA protein and the ligands that bind at the N-terminal domain (NTD) - C-terminal domain (CTD) interface.了解HIV衣壳蛋白以及在N端结构域(NTD)-C端结构域(CTD)界面结合的配体。
RSC Med Chem. 2025 Apr 17. doi: 10.1039/d5md00111k.
6
An integrated in silico and ex vivo study identifies quinazolinedione L134716 as a potential inhibitor of infectious bronchitis virus.一项计算机模拟和体外实验相结合的研究确定喹唑啉二酮L134716为传染性支气管炎病毒的潜在抑制剂。
Vet Res Commun. 2025 Apr 22;49(3):175. doi: 10.1007/s11259-025-10742-8.
7
Phenylacetic acid metabolism in land plants: novel pathways and metabolites.陆地植物中苯乙酸的代谢:新途径与代谢产物
J Exp Bot. 2025 Mar 24. doi: 10.1093/jxb/eraf092.
8
Xylazine as an emerging new psychoactive substance; focuses on both 5-HT and κ-opioid receptors' molecular interactions and isosteric replacement.赛拉嗪作为一种新兴的新型精神活性物质;聚焦于5-羟色胺和κ-阿片受体的分子相互作用及等排取代。
Arch Pharm (Weinheim). 2025 Mar;358(3):e2500041. doi: 10.1002/ardp.202500041.
9
A monomer-dimer switch modulates the activity of plant adenosine kinase.单体-二聚体开关调节植物腺苷激酶的活性。
J Exp Bot. 2025 Aug 21;76(12):3457-3479. doi: 10.1093/jxb/eraf094.
10
Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds.新型嘧啶连接化合物的设计、合成及抗癌作用机制评估
Pharmaceuticals (Basel). 2025 Feb 19;18(2):270. doi: 10.3390/ph18020270.